ARID2 and lung carcinoma: In addition, ARID2 is also listed as one of the most frequently mutated genes after TP53, KRAS, EGFR, CDKN2A and STK11 (or LKB1) with an inactivating mutation rate ∼7.3% in lung adenocarcinomas (LUADs), the major subtype of lung cancer [14,15].